Compare DPRO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | TENX |
|---|---|---|
| Founded | 1998 | 1967 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 317.8M |
| IPO Year | 2019 | 2001 |
| Metric | DPRO | TENX |
|---|---|---|
| Price | $5.02 | $13.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $15.00 | ★ $29.67 |
| AVG Volume (30 Days) | ★ 2.1M | 923.9K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $158.69 | N/A |
| Revenue Next Year | $131.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.96 | $5.67 |
| 52 Week High | $14.37 | $18.38 |
| Indicator | DPRO | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 61.96 |
| Support Level | $4.35 | $13.16 |
| Resistance Level | $5.69 | $14.15 |
| Average True Range (ATR) | 0.47 | 0.80 |
| MACD | -0.17 | 0.30 |
| Stochastic Oscillator | 6.49 | 83.56 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.